"How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals" by Ka Kit Wong

Article

How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals

Nuclear Medicine Communications (2012)

Ka Kit Wong, University of Michigan
Amanda M. Laird, Veterans Health Administration
Amir Moubayed, University of Michigan
Sotirios Chondrogiannis, Santa Maria della Misericordia Hospital
Maria Cristina Marzola, University of Michigan
Laura Evangelista, IRCCS Istituto Oncologico Veneto - Padova
Milton D. Gross, University of Michigan
Domenico Rubello, Santa Maria della Misericordia Hospital

Link

Disciplines

Publication Date

July 1, 2012

DOI

10.1097/MNM.0B013E3283529BF7

Citation Information

Ka Kit Wong, Amanda M. Laird, Amir Moubayed, Sotirios Chondrogiannis, et al.. "How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals" Nuclear Medicine Communications Vol. 33 Iss. 7 (2012) p. 679 - 688
Available at: http://works.bepress.com/amir-moubayed/1/